Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

Overview
Headquarters

2945 Towngate Road,Suite 110,Westlake Village, CA 91361

Type of Company

Public

Employees (Worldwide)

29

Industries

Pharmaceuticals

Company Description

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.

Executives & Employees

Co-Founder

President & Chief Executive Officer

Chief Financial & Accounting Officer

Secretary & General Counsel

Chief Commercial Officer

Chief Technical Officer

Chief Medical Officer

Senior Vice President, Operations

Vice President, Investor Relations & Corporate Communications

Vice President, Marketing

Paths to Arcutis Biotherapeutics, Inc.
Potential Connections via
Relationship Science
You
Arcutis Biotherapeutics, Inc.
Owners & Shareholders
Details Hidden

Frazier Management invests in lower middle-market healthcare companies with $5-50 million in EBITDA and makes equity commitments ranging from $30-350 million. Investments take the form of buyouts, recapitalizations and corporate carveouts.

Details Hidden

Bain Capital Life Sciences is an active manager which invests in companies located in across the globe. The firm follows of biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies. Bain Capital Life Sciences provides investments in the form of inflection capital, growth capital, fallen angels and larger private equity types.

Details Hidden

OrbiMed Advisors generally seeks long-term capital appreciation through investments in companies in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm employs a disciplined investment style and achieves diversification within the global healthcare sector, with the goal of creating attractive risk-adjusted returns.

Recent Transactions
Details Hidden

Arcutis Biotherapeutics, Inc. issued USD Common Stock

Details Hidden

Arcutis Biotherapeutics, Inc. issued USD Common Stock

Details Hidden

Arcutis Biotherapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Underwriter

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Underwriter

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Associate

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Associate

Advised onArcutis Biotherapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Scientific Advisor

Chairman, Department of Dermatology at Icahn School of Medicine at Mount Sinai

Scientific Advisor

Director, Eczema & Inflammatory Disease Center at Rady Children's Hospital - San Diego

Scientific Advisor

Vice President at Astellas Pharma, Inc.

Key Stats and Financials As of 2019
Market Capitalization
$933M
Total Enterprise Value
Earnings Per Share
$-1.1
Total Equity
$101M
Total Debt
$307K
EBITDA
$-42.9M
Net Profit
$-42M
Revenue
$0
Investors
Details Hidden

Frazier Management invests in lower middle-market healthcare companies with $5-50 million in EBITDA and makes equity commitments ranging from $30-350 million. Investments take the form of buyouts, recapitalizations and corporate carveouts.

Details Hidden

Vivo Ventures invests in US-based companies. The firm targets companies operating in the fields of bio-pharmaceuticals, specialty pharmaceuticals, medical devices, and other sub-sectors of healthcare and life sciences. They provides financing for early stage capital requirements.

Suppliers
Jiangsu Hengrui Medicine Co., Ltd. Biotechnology | Lianyungang, China

Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. The company's products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection, including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections, including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; and film and gel. The company was founded in 1970 and is headquartered in Lianyungang, China.

AstraZeneca Plc Other Manufacturing | Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Arcutis Biotherapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Arcutis Biotherapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Arcutis Biotherapeutics, Inc..